drugset / Trial / NCT00567060

Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)

NCT00567060

Completed 676 enrolled UCB Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to explore in a more documented way the relative potential and efficacy of piracetam 9600 and 4800 mg daily.

Timeline

Start
2000-05
Primary completion
2004-01
Completion
2004-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Piracetam Small molecule 4800 mg
Subject Piracetam Small molecule 9600 mg

Indications